Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Shilpa Medicare Limited
WARNING LETTER
•Shilpa Medicare Limited•February 25, 2020

Shilpa Medicare Limited – FDA Warning Letter, Feb 25, 2020

Record Details

The FDA inspected Shilpa Medicare Limited, Unit-IV, from February 13-25, 2020, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** Failure to thoroughly investigate OOS results and complaints. * **OOS for Impurity:** An OOS result for impurity-(b)(4) in (b)(4) Tablets batch (b)(4) was inadequately investigated. The firm failed to identify a root cause, attributed an unknown chromatographic peak without support, and retested batches without including the original OOS batch. * **OOS for Assay:** Three batches of (b)(4) Injection showed OOS assay results. The firm concluded analytical error without sufficient scientific justification and released batches based on retest results, with inadequate CAPA details. * **Complaint Investigation - Sealing Defects:** An inadequate investigation for (b)(4) Injection batch (b)(4) where the enclosure separated from the vial, despite an unplanned deviation during manufacturing due to sealing defects. The batch was released without justification. * **Complaint Investigation - Foreign Particles:** Multiple complaints for foreign particles in (b)(4) Injection were inadequately evaluated.

Company
Shilpa Medicare Limited
Inspection date
February 25, 2020
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 2e18f8c2-80a9-409d-a285-427792df7cb5

Violation Codes10
21 CFR 21021 CFR 21121 CFR 314.81(b)(1)(ii)21 CFR 211.19221 CFR 211.198(a)FD&C Act 501(a)(2)(B)FD&C Act 505(k)21 U.S.C. 355(k)21 CFR 314.81(b)(1)(i)FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Shilpa Medicare Limited
  • 483 - 2025-11-10November 10, 2025
  • 483 - 2023-11-09November 9, 2023
  • 483 - 2020-02-13February 13, 2020
  • 483 - 2019-09-06September 6, 2019
  • 483 - 2017-11-30November 30, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Shilpa Medicare Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.